

**Table (S1): Sequence of the used primers**

Gene	Forward	Reverse
<b>CYP2B</b>	AGGAGTGTGGTGTGGGCAAA	CTACAGAGGCAGGGACACTG
<b>CCO</b>	CTCCAAGCGCCCGAGAAGTA	CCATGGCGGAAGTGGGAGAT
<b>CRTC3</b>	CTGAGCACCAAACCCCAGGA	GGGGAAAGGCAGGCCATGTAT
<b>CREB</b>	CCAGGGGTGCCAAGGATTGA	GCTCCTCCCTGGGTAATGGC
<b>BDNF</b>	CCCCGCACACTCTGTGTAGT	GCAGCCTTCATGCAACCGAA
<b>β-actin</b>	CCCAGCCATGTACGTAGCCA	CCGTCTCCGGAGTCCATCAC

CYP2B: cytochrome P450 2B, CCO: cytochrome c oxidase, CRTC3: CREB-regulated transcriptional coactivator 3, CREB: cAMP response element-binding protein, BDNF: and brain derived neurotrophic factor.

**Table (S2): Median and interquartile range of the detected genes in the studied groups**

<b>Group \ Parameter</b>	<b>Gene</b>	<b>Median</b>	<b>Interquartile range</b>
<b>Normal control</b>	CYP1A1	0.8984	0.98
	CCO	1.1549	0.55
	CRTC3	1.1208	1.35
	CREB	1.5540	1.15
	BDNF	1.1208	1.35
<b>LPS</b>	CYP1A1	0.0001 <sup>a</sup>	0.00
	CCO	0.0002 <sup>a</sup>	0.00
	CRTC3	0.0014 <sup>a</sup>	0.01
	CREB	0.0010 <sup>a</sup>	0.00
	BDNF	0.0014 <sup>a</sup>	0.01
<b>CQDs</b>	CYP1A1	0.0007 <sup>a</sup>	0.00
	CCO	0.0013 <sup>a</sup>	0.00
	CRTC3	0.0058 <sup>a</sup>	0.01
	CREB	0.0031 <sup>a</sup>	0.01
	BDNF	0.0058 <sup>a</sup>	0.01
<b>Early free VRH</b>	CYP1A1	0.3234 <sup>b, c</sup>	0.36
	CCO	0.0063 <sup>a</sup>	0.01
	CRTC3	0.1070 <sup>b, c</sup>	0.17
	CREB	0.0801 <sup>a, b</sup>	0.11
	BDNF	0.1070 <sup>a, b, c</sup>	0.17
<b>Late free VRH</b>	CYP1A1	0.0229 <sup>a</sup>	0.04
	CCO	0.0020 <sup>a</sup>	0.01
	CRTC3	0.0389 <sup>a</sup>	0.08
	CREB	0.0657 <sup>a, b</sup>	0.10
	BDNF	0.0389 <sup>a</sup>	0.08
<b>Early VCQDs</b>	CYP1A1	0.8017 <sup>b, c, e</sup>	0.92
	CCO	0.5822 <sup>b, c, d, e</sup>	1.80
	CRTC3	0.2640 <sup>b, c, e</sup>	0.50
	CREB	0.7649 <sup>b, c, d, e</sup>	1.24
	BDNF	0.2640 <sup>b, c, e</sup>	0.50
<b>Late VCQDs</b>	CYP1A1	0.1949 <sup>b, c</sup>	0.39
	CCO	0.0636 <sup>b, c, e</sup>	0.10
	CRTC3	0.1667 <sup>b, c</sup>	0.24
	CREB	0.2831 <sup>b, c</sup>	0.64
	BDNF	0.1667 <sup>b, c</sup>	0.24

Kruskal-Wallis test followed by Dunn's test between groups. n = 6, P < 0.05. a: significant vs. normal control, b: significant vs. LPS, c: significant vs. CQDs, d: significant vs. early FVRP, e: significant vs. late FVRP, f: significant vs. early VCQDs. LPS: lipopolysaccharides, CQDs: hyaluronic acid caron quantum dots, FVRH: free verapamil, VCQDs: verapamil-loaded CQDs, CYP1A1: cytochrome P1A1, CCO: cytochrome c oxidase, CRTC3: CREB-regulated transcriptional coactivator 3, CREB: cAMP response element-binding protein, BDNF: brain-derived neurotrophic factor.